Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders
August 03 2020 - 4:15PM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
commercial-stage biopharmaceutical company focused on developing
and commercializing innovative therapies for people with rare
debilitating, chronic neuromuscular and neurological diseases,
today announced a change in the format of its 2020 Annual Meeting
of Stockholders (the "Annual Meeting") from an in-person meeting to
a virtual-only meeting format. The change is being made as a result
of the coronavirus outbreak (COVID-19) and in order to protect the
health and safety of Catalyst's stockholders and employees. There
will be no in-person meeting. As previously announced, the Annual
Meeting will be held on Thursday, August 20, 2020 at 9:00 a.m.
eastern time.
Stockholders will be able to attend the Annual
Meeting and submit questions and vote their shares during the
Annual Meeting, from any location that has internet connectivity.
Only stockholders of record at the close of business on June 22,
2020 ("Record Date") will be entitled to attend the virtual Annual
Meeting. To register for the Annual Meeting, you should follow
these instructions as applicable to the nature of your ownership of
our common stock:
- Registered Stockholders. If your shares are
registered in your name with Continental Stock Transfer & Trust
Company ("Continental"), and you wish to attend the online-only
virtual Annual Meeting, go to www.cstproxy.com/catalystpharma/2020,
enter the control number you received on your proxy card (printed
in the box and marked with an arrow) and click on the "Click Here
to Preregister for the Online Meeting" link at the top of the page.
Just prior to the start of the meeting you will need to log back
into the meeting site using your control number. Pre-registration
is recommended but is not required to attend.
- Street Name Stockholders. Street name
stockholders who wish to attend the online-only virtual Annual
Meeting must obtain a legal proxy by contacting their account
representative at the bank, broker, or other nominee that holds
their shares and email a copy (a legible photograph is sufficient)
of their legal proxy to proxy@continentalstock.com. Street name
stockholders who email a valid legal proxy will be issued a meeting
control number that will allow them to register to attend and
participate in the online-only Annual Meeting. After contacting
Continental, a street name stockholder will receive an e-mail prior
to the meeting with a link and instructions for entering the
virtual Annual Meeting. Street name stockholders should contact
Continental at least five (5) business dates prior to the Annual
Meeting date.
Stockholders participating in the virtual Annual
Meeting will be in a listen-only mode and will not be able to speak
during the webcast. However, in order to maintain the interactive
nature of the virtual meeting, virtual attendees are able to: (i)
vote using the online meeting website, and (ii) submit questions or
comments to Catalyst's officers during the meeting via e-mail or
the virtual meeting webcast. Starting Monday, August 17, 2020 at
9:00 AM eastern time, stockholders may submit questions or comments
before or during the meeting through the virtual meeting portal by
typing in the "Submit a Question" box.
Stockholders will also have the option to call
in to the virtual Annual Meeting by telephone and listen (in
listen-only mode) by calling:
|
Within the
U.S. and Canada |
1-888-965-8995
(toll free) |
|
|
Outside the U.S. and Canada |
1-415-655-0243 (standard rates apply) |
|
|
Passcode for telephone access: |
09485747# |
|
We encourage you to access the Annual Meeting 15
minutes prior to the start time. Online check-in will begin at 8:45
a.m. eastern time.
On or about July 6, 2020, Catalyst filed with
the SEC and mailed to its stockholders a proxy statement (the
"Proxy Statement") containing information about the matters to be
considered at the Annual Meeting. In connection with the matters
described in this press release, Catalyst is filing with the SEC
and making available to its stockholders a supplement to its Proxy
Statement ("Supplement") containing additional information about
the matters to be considered at the Annual Meeting. Catalyst's
Proxy Statement, its Supplement, and its annual report for the year
ended December 31, 2019, are available for download on Catalyst's
website at
https://ir.catalystpharma.com/financial-information/annual-reports
and on Continental's website at
https://www.cstproxy.com/catalystpharma/2020.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, including Lambert-Eaton
myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia
gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3.
Catalyst's new drug application for Firdapse® (amifampridine) 10 mg
tablets for the treatment of adults with LEMS was approved in
November 2018 by the U.S. Food & Drug
Administration ("FDA"), and Firdapse is now commercially
available in the United States. Prior to its approval,
Firdapse for LEMS had received breakthrough therapy designation and
orphan drug designation from the FDA.
Firdapse is currently being evaluated in
clinical trials for the treatment of MuSK-MG and SMA Type 3 and has
received Orphan Drug Designation from the FDA for
myasthenia gravis.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2019 and Catalyst's
other filings with the U.S. Securities and Exchange
Commission (SEC), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024